AR039562A1 - OXO-AZABICICLIC COMPOUNDS - Google Patents
OXO-AZABICICLIC COMPOUNDSInfo
- Publication number
- AR039562A1 AR039562A1 ARP030100749A ARP030100749A AR039562A1 AR 039562 A1 AR039562 A1 AR 039562A1 AR P030100749 A ARP030100749 A AR P030100749A AR P030100749 A ARP030100749 A AR P030100749A AR 039562 A1 AR039562 A1 AR 039562A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- oxygen
- atom
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 19
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- 239000001257 hydrogen Substances 0.000 abstract 13
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 229910052760 oxygen Inorganic materials 0.000 abstract 11
- 229910052717 sulfur Inorganic materials 0.000 abstract 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 10
- 239000001301 oxygen Substances 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 6
- 239000011593 sulfur Substances 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 5
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- -1 hydroxy, cyano, tetrazolyl Chemical group 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical compound C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos oxo-azabicíclicos y su uso para la preparación de una composición farmacéutica para tratar la inhibición de la metaloproteasa de la matriz de tipo 13, mediante la administración a un cuerpo vivo de una cantidad eficaz de dicho compuesto. La composición farmacéutica es útil para el tratamiento de una enfermedad seleccionada de artritis, osteoartritis y otras de acuerdo con la memoria. Composición farmacéutica que comprende una cantidad eficaz de dicho compuesto solo o en combinación con uno o más excipientes o portadores farmacéuticamente aceptables. Reivindicación 1: Un compuesto seleccionado de aquellos de fórmula (1), caracterizado porque: X1, X2, y X3, independientemente uno de otro, representan un átomo de nitrógeno o un grupo -CR3 en donde R3 representa un grupo seleccionado de hidrógeno, alquilo C1-6, amino, monoalquilamino C1-6, dialquilamino C1-6, hidroxi, alcoxi C1-6, y halógeno, con la condición de que no más de dos de los grupos X1, X2, y X3 simultáneamente representa un átomo de nitrógeno; G1 representa un grupo seleccionado entre las fórmulas (2) y (3) en donde: el átomo de carbono con el número 2 está unido al grupo N-R1 del anillo, R4 y R5, idénticos o diferentes, independientemente uno del otro, representa un grupo seleccionado de hidrógeno, alquilo C1-6, arilo, arilalquilo C1-6, cicloalquilo, cicloalquilalquilo C1-6, heteroarilo, heteroarilalquilo C1-6, heterocicloalquilo, y heterocicloalquilalquilo C1-6, R6 representa un grupo seleccionado de: hidrógeno, trifluorometilo, OR7, NR7R8, en donde R7 y R8, idénticos o diferentes independientemente uno del otro, representan hidrógeno o alquilo C1-6; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, arilalquilo C1-6, cicloalquilalquilo C1-6, heteroarilo, heteroarilalquilo C1-6, heterocicloalquilo, y heterocicloalquilalquilo C1-6, estos grupos siendo opcionalmente substituidos por uno o más grupos, que pueden ser idénticos o diferentes independientemente uno del otro, seleccionados de halógeno, amino, monoalquilamino C1-6, dialquilamino C1-6, cada grupo alquilo es idéntico o diferente independientemente uno del otro, ciano, trihalogenoalquilo C1-6, acilo C1-6, -C(-O)OR7, -OR7 y -SR7, en donde R7 es lo definido anteriormente, G2 representas un grupo seleccionado de triple enlace carbono-carbono, -CH=C=CH-, C=O, C=S, S(O)n1 en donde n1 representa un entero de 0 a 2 inclusive, y un grupo de fórmula (4), en donde el átomo de carbono con el número 1 está unido al biciclo del compuesto de fórmula (1), Y1 representa un grupo seleccionado de oxígeno, azufre, -NH y -Nalquilo C1-6, e Y2 representa un grupo seleccionado de oxígeno, azufre, -NH y -Nalquilo C1-6, n representa un entero de 0 a 6 inclusive, Z1 representa -CR9R10, en donde R9 y R10, idénticos o diferentes independientemente uno del otro, representan un grupo seleccionado de hidrógeno, alquilo C1-6, trihalogenoalquilo C1-6, halógeno, -OR7, -SR7, y -C(-O)OR7, en donde R7 es lo definido anteriormente, amino, monoalquilamino C1-6, dialquilamino C1-6 en donde cada grupo alquilo es idéntico o diferente independientemente uno del otro, y en donde cuando n es mayor o igual a 2, la cadena hidrocarbonada Z1 opcionalmente contiene uno a dos enlaces múltiples aislados o conjugados, y/o en donde cuando n es mayor o igual a 2, uno de dichos -CR9R10 pueden opcionalmente ser reemplazados con un grupo seleccionado de oxígeno, S(O)n1 en donde n1 es lo definido anteriormente, -NH y -Nalquilo C1-6, A representa un grupo seleccionado de arilo, heteroarilo, cicloalquilo, y heterocicloalquilo, estos grupos son monociclos o biciclos de 5- o 6-miembros compuestos de dos monociclos de 5- o 6-miembros, R1 representa un grupo seleccionado de: hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, estos grupos pueden estar opcionalmente substituidos con uno o más grupos, que pueden ser idénticos o diferentes independientemente uno del otro, seleccionado de amino, ciano, trihalogenoalquilo C1-6, cicloalquilo, -C(=O)NR7R8, -C(=O)OR8, OR8, SR8, en donde R7 y R8, que pueden ser idénticos o diferentes independientemente uno del otro, representa hidrógeno o alquilo C1-6, y el grupo de fórmula (5), en donde p es un entero de 0 a 8 inclusive, Z2 representa -CR11R12 en donde R11 y R12, idénticos o diferentes independientemente uno del otro, representa un grupo seleccionado de hidrógeno, alquilo C1-6, fenilo, trihalogenoalquilo C1-6, halógeno, amino, OR7, SR7 y -C(-O)OR7 en donde R7 representa hidrógeno o alquilo C1-6, y en donde cuando p es mayor o igual a 2, la cadena hidrocarbonada Z2 opcionalmente contiene uno a dos enlaces múltiples aislados o conjugados, y/o cuando n es mayor o igual a 2, uno de dichos -CR11R12 pueden opcionalmente ser reemplazado con un grupo seleccionado de oxígeno, S(O)n1 en donde n1 es lo definido anteriormente, -NH, -Nalquilo C1-6, y carbonilo, B representa un grupo seleccionado de arilo, heteroarilo, cicloalquilo, y heterocicloalquilo, estos grupos son monociclos o biciclos de 5 o 6 miembros compuestos de dos monociclos de 5 o 6 miembros, q es un entero de 0 a 7 inclusive, el grupo(s) G3, que puede ser idéntico o diferente independientemente uno del otro, se selecciona(n) de alquilo C1-6, halógeno, CN, NO2, CF3, OCF3, -(CH2)kNR13R14, -N(R13)C(=O)R14, -N(R13)C(=O)OR14, -N(R13)SO2R14, -N(SO2R13)2, -OR13, -S(O)k1R13, -SO2-N(R13)-(CH2)k2-NR14R15, -(CH2)kSO2NR13R14, -X4(CH2)kC(=O)OR13, -(CH2)kC(=O)OR13, -C(=O)O-(CH2)k2-NR13R14, -C(=O)O-(CH2)k2-C(=O)OR16, -X4(CH2)kC(=O)NR13R14, -(CH2)kC(=O)NR13R14, -R17-C(=O)OR13, -X5-R18, y -C(=O)-R19-NR13R14 en donde: X4 representa un grupo seleccionado de un átomo de oxígeno, un átomo de azufre opcionalmente substituidos por uno o dos átomos de oxígeno, y un átomo de nitrógeno substituido por un átomo de hidrógeno o un grupo alquilo C1-6, k es un entero de 0 a 3 inclusive, k1 es un entero de 0 a 2 inclusive, k2 es un entero de 1 a 4 inclusive, R13, R14 y R15, que pueden ser idénticos o diferentes independientemente uno del otro, están seleccionados de hidrógeno y alquilo C1-6, R16 representa un grupo seleccionado de alquiloC1-6, -R19-NR13R14, -R19-NR13-C(=O)-R19-NR14R15, y -C(=O)O-R19-NR13R14 en donde R19 representa un grupo alquileno C1-6 lineal o ramificado, y R13, R14 y R15 son lo definido anteriormente, R17 representa un grupo cicloalquilo C3-6, X5 representa un grupo seleccionado de un solo enlace, -CH2-, un átomo de oxígeno, un átomo de azufre opcionalmente substituido por uno o dos átomos de oxígeno, y un átomo de nitrógeno substituido por un átomo de hidrógeno o un grupo alquilo C1-6, R18 representa un grupo seleccionado de: monociclo de 5 o 6 miembros arilo, heteroarilo, que es opcionalmente substituido por uno o más grupos, que pueden ser idénticos o diferentes, seleccionados de alquilo C1-6, halógeno, hidroxi, ciano, tetrazolilo, amino, y -C(=O)OR7 en donde R7 representa hidrógeno o alquilo C1-6, y monociclo de 5- o 6- miembros cicloalquilo, heterocicloalquilo, que es opcionalmente substituido por uno o más grupos, que pueden ser idénticos o diferentes, seleccionados de alquilo C1-6, halógeno, hidroxi, oxo, ciano, tetrazolilo, amino, y -C(=O)OR7 en donde R7 representa hidrógeno o alquilo C1-6, m es un entero de 0 a 7 inclusive, el grupo(s) R2, que pueden ser idénticos o diferentes independientemente uno del otro, se seleccionan de alquilo C1-6, halógeno, -CN, NO2, SCF3, -CF3, -OCF3, -NR7R8, -OR8, -SR8, -SOR8, -SO2R8, -(CH2)kSO2NR7R8, -X7(CH2)kC(=O)OR8, -(CH2)kC(=O)OR8, -X7(CH2)kC(=O)NR7R8, -(CH2)kC(=O)NR7R8, y -X8-R20 en donde: X7 representa un grupo seleccionado de oxígeno, azufre opcionalmente substituido por uno o dos átomos de oxígeno, y un átomo de nitrógeno substituido por un átomo de hidrógeno o un grupo alquilo C1-6, k es un entero de 0 a 3 inclusive, R7 y R8, que pueden ser idénticos o diferentes independientemente uno del otro, se seleccionan de hidrógeno y alquilo C1-6, X8 representa un grupo seleccionado de un solo enlace, -CH2-, un átomo de oxígeno, un átomo de azufre opcionalmente substituido por uno o dos átomos de oxígeno, y un átomo de nitrógeno substituido por un átomo de hidrógeno o un grupo alquilo C1-6, R20 representa un monociclo de 5- o 6- miembros arilo, heteroarilo, cicloalquilo, o heterocicloalquilo que es opcionalmente substituido por uno o más grupos, que pueden ser idénticos o diferentes, seleccionados de alquilo C1-6, halógeno, hidroxi y amino, y cuando el anillo es heterocíclico, comprende de 1 a 4 heteroátomos seleccionados de nitrógeno, oxígeno y azufre, opcionalmente, las formas racémicas de ellos, isómeros de ellos, N-óxidos de ellos y la sales farmacéuticamente aceptables de ellos, entendiéndose que cuando no se describe ninguna especificación: un grupo arilo indica un sistema monocíclico o bicíclico aromático que contiene de 5 a 10 átomos de carbono, y en el caso de un sistema bicíclico, uno de los anillos es de carácter aromático, y el otro anillo puede ser aromático o parcialmente hidrogenado, un grupo heteroarilo indica un grupo arilo descripto anteriormente en donde de 1 a 4 átomos de carbono son reemplazados por 1 a 4 heteroátomos seleccionados de oxígeno, azufre y nitrógeno, un grupo cicloalquilo indica un sistema monocíclico o bicíclico que contiene de 3 a 10 átomos de carbono, este sistema es saturado o parcialmente insaturado pero sin carácter aromático, y un grupo heterocicloalquilo indica un grupo cicloalquilo definido anteriormente en donde de 1 a 4 átomos de carbono son reemplazados por 1 a 4 heteroátomos seleccionados de oxígeno, azufre, y nitrógeno.Oxo-azabicyclic compounds and their use for the preparation of a pharmaceutical composition to treat the inhibition of type 13 matrix metalloprotease, by administration to a living body of an effective amount of said compound. The pharmaceutical composition is useful for the treatment of a disease selected from arthritis, osteoarthritis and others according to memory. Pharmaceutical composition comprising an effective amount of said compound alone or in combination with one or more pharmaceutically acceptable excipients or carriers. Claim 1: A compound selected from those of formula (1), characterized in that: X1, X2, and X3, independently of one another, represent a nitrogen atom or a -CR3 group wherein R3 represents a selected group of hydrogen, alkyl C1-6, amino, C1-6 monoalkylamino, C1-6 dialkylamino, hydroxy, C1-6 alkoxy, and halogen, with the proviso that no more than two of the groups X1, X2, and X3 simultaneously represent a nitrogen atom ; G1 represents a group selected from formulas (2) and (3) in which: the carbon atom with the number 2 is attached to the N-R1 group of the ring, R4 and R5, identical or different, independently of each other, represents a group selected from hydrogen, C 1-6 alkyl, aryl, C 1-6 arylalkyl, cycloalkyl, C 1-6 cycloalkylalkyl, heteroaryl, C 1-6 heteroarylalkyl, heterocycloalkyl, and C 1-6 heterocycloalkylalkyl, R 6 represents a group selected from: hydrogen, trifluoromethyl , OR7, NR7R8, wherein R7 and R8, identical or different independently of each other, represent hydrogen or C1-6 alkyl; C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, C 1-6 arylalkyl, C 1-6 cycloalkylalkyl, heteroaryl, C 1-6 heteroarylalkyl, heterocycloalkyl, and C 1-6 heterocycloalkylalkyl, these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from halogen, amino, C1-6 monoalkylamino, C1-6 dialkylamino, each alkyl group is identical or different independently from each other, cyano, C1-6 trihalogenoalkyl, acyl C1-6, -C (-O) OR7, -OR7 and -SR7, where R7 is defined above, G2 represents a selected group of carbon-carbon triple bond, -CH = C = CH-, C = O, C = S, S (O) n1 where n1 represents an integer from 0 to 2 inclusive, and a group of formula (4), where the carbon atom with the number 1 is attached to the bicycles of the compound of formula (1 ), Y1 represents a group selected from oxygen, sulfur, -NH and -C 1-6 alkyl, and Y2 represents a group selected from oxygen or, sulfur, -NH and -C1-6alkyl, n represents an integer from 0 to 6 inclusive, Z1 represents -CR9R10, where R9 and R10, identical or different independently of each other, represent a group selected from hydrogen, alkyl C1-6, trihalogeno C1-6 alkyl, halogen, -OR7, -SR7, and -C (-O) OR7, where R7 is defined above, amino, C1-6 monoalkylamino, C1-6 dialkylamino where each alkyl group is identical or different independently of each other, and where when n is greater than or equal to 2, the hydrocarbon chain Z1 optionally contains one to two isolated or conjugated multiple bonds, and / or where when n is greater than or equal to 2, one of said -CR9R10 can optionally be replaced with a selected group of oxygen, S (O) n1 where n1 is as defined above, -NH and -C1-6alkyl, A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups are 5- or 6-membered monocycles or bicycles composed of two 5- or 6-membered monocycles, R 1 represents a group selected from: hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, these groups may be optionally substituted with one or more groups, which may be identical or different independently of each other, selected from amino, cyano, trihalogeno C1-6 alkyl, cycloalkyl, -C (= O) NR7R8, -C (= O) OR8, OR8, SR8, where R7 and R8, which may be identical or different independently of each other, represents hydrogen or C1-6 alkyl, and the group of formula (5), where p is an integer from 0 to 8 inclusive, Z2 represents -CR11R12 wherein R11 and R12, identical or different independently one of the other represents a group selected from hydrogen, C1-6 alkyl, phenyl, trihalogenoalkyl C1-6 alkyl, halogen, amino, OR7, SR7 and -C (-O) OR7 wherein R7 represents hydrogen or C1-6 alkyl, and where when p is greater than or equal to 2, the hydrocarbon chain Z2 optionally contains one to two isolated multiple bonds or conjugates, and / or when n is greater than or equal to 2, one of said -CR11R12 may optionally be replaced with a selected group of oxygen, S (O) n1 wherein n1 is as defined above, -NH, -C1 -alkyl 6, and carbonyl, B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups are 5 or 6 member monocycles or bicycles composed of two 5 or 6 member monocycles, which is an integer from 0 to 7 inclusive , the group (s) G3, which may be identical or different independently from each other, is selected from C1-6 alkyl, halogen, CN, NO2, CF3, OCF3, - (CH2) kNR13R14, -N (R13 ) C (= O) R14, -N (R13) C (= O) OR14, -N (R13) SO2R14, -N (SO2R13) 2, -OR13, -S (O) k1R13, -SO2-N (R13 ) - (CH2) k2-NR14R15, - (CH2) kSO2NR13R14, -X4 (CH2) kC (= O) OR13, - (CH2) kC (= O) OR13, -C (= O) O- (CH2) k2 -NR13R14, -C (= O) O- (CH2) k2-C (= O) OR16, -X4 (CH2) kC (= O) NR13R14, - (CH2) kC (= O) NR13R14, -R17-C (= O) OR13, -X5-R18, and -C (= O) -R19-NR13R14 where: X4 represents a selected group of an atom d and oxygen, a sulfur atom optionally substituted by one or two oxygen atoms, and a nitrogen atom substituted by a hydrogen atom or a C1-6 alkyl group, k is an integer from 0 to 3 inclusive, k1 is an integer from 0 to 2 inclusive, k2 is an integer from 1 to 4 inclusive, R13, R14 and R15, which can be identical or different independently from each other, are selected from hydrogen and C1-6 alkyl, R16 represents a group selected from C1-alkyl -6, -R19-NR13R14, -R19-NR13-C (= O) -R19-NR14R15, and -C (= O) O-R19-NR13R14 where R19 represents a linear or branched C1-6 alkylene group, and R13, R14 and R15 are as defined above, R17 represents a C3-6 cycloalkyl group, X5 represents a group selected from a single bond, -CH2-, an oxygen atom, a sulfur atom optionally substituted by one or two atoms of oxygen, and a nitrogen atom substituted by a hydrogen atom or a C1-6 alkyl group, R18 represents a select group do of: 5 or 6-membered aryl, heteroaryl monocycle, which is optionally substituted by one or more groups, which may be identical or different, selected from C1-6 alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and -C (= O) OR7 wherein R7 represents hydrogen or C1-6 alkyl, and 5- or 6- membered cycloalkyl, heterocycloalkyl monocycle, which is optionally substituted by one or more groups, which may be identical or different, selected from C1 alkyl -6, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and -C (= O) OR7 wherein R7 represents hydrogen or C1-6 alkyl, m is an integer from 0 to 7 inclusive, the group (s) R2 , which may be identical or different independently of each other, are selected from C1-6 alkyl, halogen, -CN, NO2, SCF3, -CF3, -OCF3, -NR7R8, -OR8, -SR8, -SOR8, -SO2R8, - (CH2) kSO2NR7R8, -X7 (CH2) kC (= O) OR8, - (CH2) kC (= O) OR8, -X7 (CH2) kC (= O) NR7R8, - (CH2) kC (= O) NR7R8, and -X8-R20 where: X7 represents a selected group of oxygen, sulfur opc ionically substituted by one or two oxygen atoms, and a nitrogen atom substituted by a hydrogen atom or a C1-6 alkyl group, k is an integer from 0 to 3 inclusive, R7 and R8, which may be identical or different independently from each other, hydrogen and C1-6 alkyl are selected, X8 represents a group selected from a single bond, -CH2-, an oxygen atom, a sulfur atom optionally substituted by one or two oxygen atoms, and an atom of nitrogen substituted by a hydrogen atom or a C1-6 alkyl group, R20 represents a 5- or 6- membered aryl, heteroaryl, cycloalkyl, or heterocycloalkyl monocycle which is optionally substituted by one or more groups, which may be identical or different, selected from C1-6 alkyl, halogen, hydroxy and amino, and when the ring is heterocyclic, it comprises 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, optionally, the racemic forms thereof, isomers of them, their N-oxides and the pharmaceutically acceptable salts thereof, it being understood that when no specification is described: an aryl group indicates an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the rings is aromatic, and the other ring can be aromatic or partially hydrogenated, a heteroaryl group indicates an aryl group described above where 1 to 4 carbon atoms are replaced by 1 to 4 selected heteroatoms of oxygen, sulfur and nitrogen, a cycloalkyl group indicates a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, this system is saturated or partially unsaturated but without aromatic character, and a heterocycloalkyl group indicates a cycloalkyl group defined above where 1 to 4 carbon atoms are replaced by 1 to 4 heteroatoms selected from oxygen, sulfur, and nitrog eno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/003240 WO2003076416A1 (en) | 2002-03-08 | 2002-03-08 | Oxo azabicyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039562A1 true AR039562A1 (en) | 2005-02-23 |
Family
ID=27798761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100749A AR039562A1 (en) | 2002-03-08 | 2003-03-06 | OXO-AZABICICLIC COMPOUNDS |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1492775A2 (en) |
| JP (1) | JP2005526070A (en) |
| KR (1) | KR20040095270A (en) |
| CN (1) | CN1738806A (en) |
| AP (1) | AP2004003125A0 (en) |
| AR (1) | AR039562A1 (en) |
| AU (2) | AU2002249275A1 (en) |
| BR (1) | BR0308280A (en) |
| CA (1) | CA2478706A1 (en) |
| CO (1) | CO5601020A2 (en) |
| EA (1) | EA200401053A1 (en) |
| EC (1) | ECSP045278A (en) |
| IL (1) | IL163818A0 (en) |
| IS (1) | IS7414A (en) |
| MA (1) | MA27183A1 (en) |
| MX (1) | MXPA04008681A (en) |
| NO (1) | NO20044041L (en) |
| OA (1) | OA12782A (en) |
| PA (1) | PA8568501A1 (en) |
| PE (1) | PE20031018A1 (en) |
| PL (1) | PL372622A1 (en) |
| SV (1) | SV2003001495A (en) |
| TN (1) | TNSN04169A1 (en) |
| UY (1) | UY27700A1 (en) |
| WO (2) | WO2003076416A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (en) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | TRIAZOLO COMPOUNDS AS MMP INHIBITORS |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| BR0313384A (en) | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Chromone derivatives as matrix metalloproteinase inhibitors |
| WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| JP2006504665A (en) | 2002-08-13 | 2006-02-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| PA8578101A1 (en) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS |
| JP2006500351A (en) | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase-13 inhibitors |
| WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| DE10360835A1 (en) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
| BRPI0510305A (en) * | 2004-04-30 | 2007-10-02 | Takeda Pharmaceutical | compound or a salt thereof, prodrug or a salt thereof, pharmaceutical agent, method of producing the compound or a salt thereof, matrix metalloproteinase inhibitor or a salt thereof or a prodrug thereof, method of inhibiting a metalloproteinase matrix, and use of a compound or salt thereof or a prodrug thereof |
| WO2005123696A1 (en) * | 2004-06-15 | 2005-12-29 | Astrazeneca Ab | Substituted quinazolones as anti-cancer agents |
| CA2665476A1 (en) | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| WO2012052451A1 (en) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| CN103524431B (en) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-benzyl-4-quianzolinones and synthetic method thereof and application |
| JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
| EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
| FR3046793B1 (en) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0946095A1 (en) * | 1996-12-17 | 1999-10-06 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
| PA8539401A1 (en) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | QUINAZOLINAS AS INHIBITORS OF MMP-13 |
| PA8539301A1 (en) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX |
-
2002
- 2002-03-08 AU AU2002249275A patent/AU2002249275A1/en not_active Abandoned
- 2002-03-08 WO PCT/EP2002/003240 patent/WO2003076416A1/en not_active Ceased
-
2003
- 2003-03-04 SV SV2003001495A patent/SV2003001495A/en not_active Application Discontinuation
- 2003-03-06 PL PL03372622A patent/PL372622A1/en not_active Application Discontinuation
- 2003-03-06 EP EP03708181A patent/EP1492775A2/en not_active Withdrawn
- 2003-03-06 CN CNA038048752A patent/CN1738806A/en active Pending
- 2003-03-06 AU AU2003212307A patent/AU2003212307A1/en not_active Abandoned
- 2003-03-06 PA PA20038568501A patent/PA8568501A1/en unknown
- 2003-03-06 IL IL16381803A patent/IL163818A0/en unknown
- 2003-03-06 MX MXPA04008681A patent/MXPA04008681A/en unknown
- 2003-03-06 KR KR10-2004-7013994A patent/KR20040095270A/en not_active Ceased
- 2003-03-06 OA OA1200400234A patent/OA12782A/en unknown
- 2003-03-06 AP APAP/P/2004/003125A patent/AP2004003125A0/en unknown
- 2003-03-06 PE PE2003000218A patent/PE20031018A1/en not_active Application Discontinuation
- 2003-03-06 CA CA002478706A patent/CA2478706A1/en not_active Abandoned
- 2003-03-06 AR ARP030100749A patent/AR039562A1/en not_active Application Discontinuation
- 2003-03-06 JP JP2003574636A patent/JP2005526070A/en not_active Withdrawn
- 2003-03-06 EA EA200401053A patent/EA200401053A1/en unknown
- 2003-03-06 UY UY27700A patent/UY27700A1/en not_active Application Discontinuation
- 2003-03-06 WO PCT/EP2003/002277 patent/WO2003076417A2/en not_active Ceased
- 2003-03-06 BR BR0308280-6A patent/BR0308280A/en not_active IP Right Cessation
-
2004
- 2004-08-19 IS IS7414A patent/IS7414A/en unknown
- 2004-08-25 CO CO04082792A patent/CO5601020A2/en not_active Application Discontinuation
- 2004-08-31 MA MA27842A patent/MA27183A1/en unknown
- 2004-09-03 TN TNP2004000169A patent/TNSN04169A1/en unknown
- 2004-09-03 EC EC2004005278A patent/ECSP045278A/en unknown
- 2004-09-24 NO NO20044041A patent/NO20044041L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20044041L (en) | 2004-10-07 |
| AU2002249275A1 (en) | 2003-09-22 |
| MA27183A1 (en) | 2005-01-03 |
| EP1492775A2 (en) | 2005-01-05 |
| JP2005526070A (en) | 2005-09-02 |
| SV2003001495A (en) | 2003-11-04 |
| WO2003076416A1 (en) | 2003-09-18 |
| AP2004003125A0 (en) | 2004-09-30 |
| CN1738806A (en) | 2006-02-22 |
| ECSP045278A (en) | 2004-10-26 |
| CA2478706A1 (en) | 2003-09-18 |
| CO5601020A2 (en) | 2006-01-31 |
| BR0308280A (en) | 2004-12-28 |
| UY27700A1 (en) | 2003-10-31 |
| OA12782A (en) | 2006-07-10 |
| PA8568501A1 (en) | 2003-12-19 |
| PE20031018A1 (en) | 2004-01-09 |
| EA200401053A1 (en) | 2005-04-28 |
| WO2003076417A2 (en) | 2003-09-18 |
| IL163818A0 (en) | 2005-12-18 |
| WO2003076417A3 (en) | 2003-11-13 |
| TNSN04169A1 (en) | 2007-03-12 |
| MXPA04008681A (en) | 2004-12-06 |
| PL372622A1 (en) | 2005-07-25 |
| KR20040095270A (en) | 2004-11-12 |
| IS7414A (en) | 2004-08-19 |
| AU2003212307A1 (en) | 2003-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039562A1 (en) | OXO-AZABICICLIC COMPOUNDS | |
| DK1263730T3 (en) | Amine derivatives for the treatment of apoptosis | |
| UY27368A1 (en) | NEW COMPOUNDS | |
| AR038476A1 (en) | QUINAZOLINE DERIVATIVES | |
| AR062640A1 (en) | AZOLCARBOXAMID COMPOUNDS AND HERBICIDE COMPOSITIONS | |
| AR025735A1 (en) | THERAPEUTIC COMPOUNDS | |
| AR029766A1 (en) | QUINASE INHIBITOR COMPOUND AND USE OF IT TO PREPARE A PHARMACEUTICAL COMPOSITION | |
| SV2002000504A (en) | REPLACED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH REF.PC10760 / 20205 / BB | |
| NO20023932D0 (en) | New connections | |
| AR068413A2 (en) | 8-AMINO DERIVATIVES, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THERAPY | |
| AR032781A1 (en) | ARILED AMIDAS OF FURAN- AND THIOPHENCHARBOXYL ACIDS, PHARMACEUTICAL COMPOSITIONS, ITS USE FOR THE PREPARATION OF MEDICINAL PRODUCT AS ALSO THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR039190A1 (en) | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT UNDERSTANDING THE COMPOUND | |
| AU5650901A (en) | Cyclohexane derivatives and their use as therapeutic agents | |
| AR037100A1 (en) | PIRIMIDINE COMPOSITE OF RENTED FUSED RING, PREPARATION PROCESS, INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USI FOR PREPARATION OF A MEDICINAL PRODUCT | |
| AR038881A1 (en) | COMPOUNDS THAT MODULATE THE ACTIVITY OF PPAR, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND A PROCEDURE FOR THE PREPARATION OF THOSE | |
| AR039226A2 (en) | USEFUL COMPOUNDS AS PREPARATION INTERMEDIARIES AND PROCEDURES | |
| AR050261A2 (en) | AMINO ACIDS AFFECTED BY THE ALFA-2-DELTA PROTEIN AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT | |
| AR016977A1 (en) | INDOL COMPOUNDS 2,3-SUBSTITUTED AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS, PHARMACEUTICAL COMPOSITIONS, USE, USEFUL INTERMEDIARIES, PREPARATION PROCEDURES | |
| ECSP045095A (en) | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF URINARY ROAD DISORDERS | |
| ECSP045420A (en) | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES OF THE SAME | |
| TR200200263T2 (en) | New selective retinoid agonists | |
| AR035756A1 (en) | USE OF CARBAMATES IN THE PREPARATION OF MEDICINES FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| PE20230412A1 (en) | COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS | |
| AR044830A1 (en) | DERIVATIVES OF 4,5 DIARIL -3-HETEROCICLILPIRAZIN- 2- ESTER | |
| PE20021018A1 (en) | DERIVATIVES OF ß - CARBOLINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |